Related Experiment Video
Updated: Aug 4, 2026
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
Targeting the Respiratory Syncytial Virus N0-P Complex with Constrained α-Helical Peptides in Cells and Mice
Marie Galloux1, Nadège Gsponer2, Vanessa Gaillard2
1VIM, INRAE, Jouy-en-Josas, France.
Insights
New stapled peptides inhibit respiratory syncytial virus (RSV) replication by blocking essential complex formation. This discovery offers a novel therapeutic strategy for RSV infection and related Mononegavirales viruses.
Area of Science:
- Virology
- Antiviral drug discovery
- Molecular biology
Background:
- Respiratory syncytial virus (RSV) is a major cause of severe respiratory illness in young children globally.
- Current RSV treatments lack approved therapies, and existing inhibitors face challenges from emergent escape mutants.
- There is a critical need for novel antiviral agents with new mechanisms of action against RSV.
Purpose of the Study:
- To identify and characterize novel inhibitors of RSV replication.
- To explore stapled peptides derived from the RSV phosphoprotein (P) as potential antiviral agents.
- To investigate the mechanism of action of these peptides in inhibiting RSV.
Main Methods:
- Design and synthesis of stapled peptides targeting the N terminus of the RSV phosphoprotein (P).
- In vitro assays to assess the inhibition of RSV replication by the stapled peptides.
- In vivo studies to evaluate the efficacy of the peptides in a model of RSV infection.
- Analysis of the mechanism of action, focusing on the N0-P complex formation.
Main Results:
- Stapled peptides derived from the RSV P protein effectively inhibit viral replication.
- These peptides function by preventing the formation of the essential N0-P complex.
- Demonstrated efficacy of the peptides in both in vitro and in vivo experimental models.
Conclusions:
- Stapled peptides represent a promising novel strategy for targeting RSV replication.
- Inhibition of N0-P complex formation is a viable mechanism for antiviral therapy against RSV.
- This approach using constrained macrocyclic peptides or small molecules is potentially applicable to other Mononegavirales viruses.
Abstract:
Respiratory syncytial virus (RSV) is the main cause of severe respiratory infection in young children worldwide, and no therapies have been approved for the treatment of RSV infection. Data from recent clinical trials of fusion or L polymerase inhibitors for the treatment of RSV-infected patients revealed the emergence of escape mutants, highlighting the need for the discovery of inhibitors with novel mechanisms of action. Here we describe stapled peptides derived from the N terminus of the phosphoprotein (P) that act as replication inhibitors. We demonstrate that these peptides inhibit RSV replication in vitro and in vivo by preventing the formation of the N0-P complex. The present strategy provides a novel means of targeting RSV replication with constrained macrocyclic peptides or small molecules and is broadly applicable to other viruses of the Mononegavirales order.
